The DOI matches its Crossref record.
Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer.
Abstract
An economic evaluation was undertaken of a previously reported National Cancer Institute of Canada (NCIC) trial of chemotherapy in advanced nonsmall-cell lung cancer (NSCLC). That trial had demonstrated a survival benefit associated with the use of either vindesine and cisplatin (VP) or cyclosphosphamide, doxorubicin, and cisplatin (CAP) in relation to best supportive care (BSC). The economic technique used in this evaluation was cost-effectiveness analysis (CEA). All costs were determined from the viewpoint of two provincial health care plans. When compared with BSC, the survival benefit of 8 weeks in favor of patients receiving CAP chemotherapy was associated with an economic saving of $949.49 (in 1984 Canadian dollars). This translated into a savings of $6,171.69 per year of life gained. The mean survival benefit of 12.8 weeks that was obtained with VP chemotherapy compared with BSC was associated with an increased cost of $3,637.60 per patient, or $14,777.75 per year of life gained. The economic evaluation demonstrated that the majority of costs on each of the three treatment arms was related to hospitalization and not to the use of chemotherapy agents. These results compare favorably with estimates of cost-effectiveness (CE) of commonly used treatments for other diseases and demonstrate that a policy of supportive care is associated with costs that may exceed those of active treatment. It is concluded that economic factors should not adversely affect decisions regarding the use of chemotherapy in advanced NSCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cella, D. F., Bonomi, A. E., Lloyd, S. R., Tulsky, D. S., Kaplan, E., & Bonomi, P. (1995) · Lung Cancer · doi:10.1016/0169-5002(95)00450-f · Cited by 750
Hoffman, P. C., Mauer, A. M., & Vokes, E. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)82038-3 · Cited by 605
Handling uncertainty when performing economic evaluation of healthcare interventions.
Briggs, & Gray (1999) · Health Technology Assessment · doi:10.3310/hta3020 · Cited by 387
D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.045 · Cited by 363
The Economics of Dying -- The Illusion of Cost Savings at the End of Life
Emanuel, E. J., & Emanuel, L. L. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402243300806 · Cited by 335
Metadata
- Authors
- Jaakkimainen, L., Goodwin, P. J., Pater, J., Warde, P., Murray, N., & Rapp, E.
- Venue
- Journal of Clinical Oncology
- Published
- 1990-08
- Volume
- 8
- Issue
- 8
- Pages
- 1301-1309
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1856909224
- Cited by
- 205
- References
- 0
- FWCI
- 31.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. https://app.cochat.ai/papers/10.1200/jco.1990.8.8.1301
- The paper
- Jaakkimainen, L., Goodwin, P. J., Pater, J., Warde, P., Murray, N., & Rapp, E. (1990). Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1990.8.8.1301
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.